ProCE Banner Activity

CME

Redefining the Possibilities for Patients With HER2-positive Gastroesophageal Cancers

Video

On-demand webcast of expert faculty presentation and case discussion on treating patients with HER2-positive gastroesophageal cancers, including strategies for utilizing biomarkers and guidelines to inform therapeutic sequencing.

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 13, 2024

Expiration: June 12, 2025

Share

Faculty

Jaffer Ajani

Jaffer Ajani, MD

Professor 
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Nataliya Uboha

Nataliya Uboha, MD, PhD

Faculty Leader for Early Phase Oncology Therapeutics Program
Associate Professor, Department of Medicine
Section of Hematology & Oncology
University of Wisconsin
Madison, Wisconsin

Zev A. Wainberg

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Target Audience

This educational program is intended for medical oncologists and other healthcare professionals who care for patients with gastrointestinal malignancies. This educational program is also intended to reach patients with GI cancer and their caregivers.  

Program Learning Goal

The goal of this activity is to educate oncologists and other healthcare professionals, patients, and caregivers on recent developments in the treatment of gastric and GEJ cancers to optimally individualize therapy.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Evaluate the importance of biomarker testing results, the latest clinical evidence, current guideline recommendations, and relevant patient-specific, disease-specific, and treatment-specific factors to aid in the development of individualized management plans for all patients with HER2-positive gastric/GEJ cancers

  • Plan evidence-based and expert-recommended therapeutic sequencing strategies for patients with HER2-positive gastric/GEJ cancers

  • Implement strategies incorporating the patient and multidisciplinary care team in the effective identification and management of treatment-related adverse events related to novel therapies for HER2-positive gastric/GEJ cancers

  • Identify patients most likely to benefit from enrollment on clinical trials with novel HER2-targeting therapies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Jaffer Ajani, MD

Professor 
Division of Cancer Medicine
Department of Gastrointestinal Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, Texas

Jaffer A. Ajani, MD: consultant/advisor/speaker: Aadi, Amgen, Astellas, AstraZeneca, BeiGene, Bristol Myers Squibb, Gilead, Jazz, Kyowa Kirin, Merck, Novartis, Servier, Zymeworks.

Nataliya Uboha, MD, PhD

Faculty Leader for Early Phase Oncology Therapeutics Program
Associate Professor, Department of Medicine
Section of Hematology & Oncology
University of Wisconsin
Madison, Wisconsin

Nataliya Uboha, MD, PhD: consultant/advisor/speaker: AstraZeneca, Arcus, Astellas, Bristol Myers Squibb, Eisai, Elevation Oncology, Ipsen, Merck, Pfizer, Strata Oncology; researcher: Arcus, Gilead, Ipsen.

Zev A. Wainberg, MD

Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
UCLA School of Medicine
Los Angeles, California

Zev A. Wainberg, MD: consultant/advisor/speaker: Alligator, Amgen, Astellas, AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, EMD Serono, Ipsen, Johnson & Johnson, Lilly, Merck, Novartis; data and safety monitoring board: AstraZeneca, Compass, Daiichi Sankyo, Mirati, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 13, 2024, through June 12, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Passport
662be69741e7b.png

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.